Literature DB >> 19230022

Endometrial cancer invasion depends on cancer-derived tumor necrosis factor-alpha and stromal derived hepatocyte growth factor.

Dong Soon Choi1, Hyun-Jin Kim, Jong-Hyuck Yoon, Seung-Chul Yoo, Hantae Jo, So Yeon Lee, Churl K Min, Hee-Sug Ryu.   

Abstract

Cancer invasion is an outcome of interactions of the cancer and the host cell. It is now becoming increasingly clear that ovarian hormones have a huge influence on such intercommunications in various types of cancers. Estrogen is known to aggravate the aggressiveness of the endometrial cancer whereas progesterone seems to act as a negative factor. Insight into the mode of ovarian hormonal actions could come from the studies of its regulation of the paracrine interactions between the endometrial cancer and the normal stromal cells during the cancer invasion. In this context, we report here that estrogen promotes the endometrial cancer invasion by inducing humoral interactions between the cancer and the stromal cells, i.e., estrogen stimulates tumor necrosis factor-alpha expression from the endometrial cancer cells, which, in turn, induces the stromal expression of hepatocyte growth factor (HGF), conferring the enhanced NK4 (HGF-antagonist/angiogenesis inhibitor)-sensitive invasion characteristic of the endometrial cancer cells. Additionally, we demonstrate a close correlation of the invasion of endometrial cancer cells with the expression and dimerization of integrin alpha(v)beta(5) as well as the activation of focal adhesion kinase as the consequences of paracrine interactions. Thus, understanding of paracrine interactions of cancer cells with host stromal cells can yield new insight into the architecture and function of cancer invasion and metastasis, leading to a development of a new cancer therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19230022     DOI: 10.1002/ijc.24238

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  13 in total

1.  Expression of αV-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-αV-integrin antibody.

Authors:  Marta Bellone; Emiliano Cocco; Joyce Varughese; Stefania Bellone; Paola Todeschini; Karim El-Sahwi; Luisa Carrara; Federica Guzzo; Peter E Schwartz; Thomas J Rutherford; Sergio Pecorelli; Deborah J Marshall; Alessandro D Santin
Journal:  Int J Gynecol Cancer       Date:  2011-08       Impact factor: 3.437

Review 2.  Future directions in the field of endometrial cancer research: the need to investigate the tumor microenvironment.

Authors:  A S Felix; J Weissfeld; R Edwards; F Linkov
Journal:  Eur J Gynaecol Oncol       Date:  2010       Impact factor: 0.196

Review 3.  Molecular cues on obesity signals, tumor markers and endometrial cancer.

Authors:  Danielle Daley-Brown; Gabriela M Oprea-Ilies; Regina Lee; Roland Pattillo; Ruben R Gonzalez-Perez
Journal:  Horm Mol Biol Clin Investig       Date:  2015-01

4.  Serous carcinomatous component championed by heparin-binding EGF-like growth factor (HB-EGF) predisposing to metastasis and recurrence in stage I uterine malignant mixed mullerian tumor.

Authors:  Lei Zhang; David Shimizu; Jeffrey L Killeen; Stacey A Honda; Di Lu; Alexander Stanoyevitch; Fritz Lin; Beverly Wang; Edwin S Monuki; Michele Carbone
Journal:  Hum Pathol       Date:  2016-03-11       Impact factor: 3.466

5.  IL6 Induces mtDNA Leakage to Affect the Immune Escape of Endometrial Carcinoma via cGAS-STING.

Authors:  Xue Zeng; Xiaosong Li; Yundong Zhang; Chaoxia Cao; Qin Zhou
Journal:  J Immunol Res       Date:  2022-06-02       Impact factor: 4.493

6.  The clinical significance of inflammatory cytokines in primary cell culture in endometrial carcinoma.

Authors:  Harriet O Smith; Nicole D Stephens; Clifford R Qualls; Tal Fligelman; Tao Wang; Chang-Yun Lin; Elizabeth Burton; Jeffrey K Griffith; Jeffrey W Pollard
Journal:  Mol Oncol       Date:  2012-08-15       Impact factor: 6.603

7.  Prognostic value of tumor growth factor levels during chemotherapy in patients with metastatic colorectal cancer.

Authors:  Mevlüde Inanç; Ozlem Er; Halit Karaca; Veli Berk; Metin Ozkan; Recep Saraymen; Ferhan Elmalı
Journal:  Med Oncol       Date:  2012-05-12       Impact factor: 3.064

8.  Supervised Clustering of Adipokines and Hormonal Receptors Predict Prognosis in a Population of Obese Women with Type 1 Endometrial Cancer.

Authors:  Jennifer Uzan; Enora Laas; Issam Abd Alsamad; Dounia Skalli; Dhouha Mansouri; Bassam Haddad; Cyril Touboul
Journal:  Int J Mol Sci       Date:  2017-05-13       Impact factor: 5.923

Review 9.  Hepatocyte Growth Factor Isoforms in Tissue Repair, Cancer, and Fibrotic Remodeling.

Authors:  Ognoon Mungunsukh; Elizabeth A McCart; Regina M Day
Journal:  Biomedicines       Date:  2014-11-05

10.  Overexpression of MACC1 leads to downstream activation of HGF/MET and potentiates metastasis and recurrence of colorectal cancer.

Authors:  Lisa A Boardman
Journal:  Genome Med       Date:  2009-04-02       Impact factor: 11.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.